Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
4.1
Journals
JPM
Special Issues
New Insights into Targeted Therapy and Immunotherapy for Non-Small-Cell Lung...
share announcement

New Insights into Targeted Therapy and Immunotherapy for Non-Small-Cell Lung Cancer

A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Molecular Targeted Therapy".

Deadline for manuscript submissions: closed (31 March 2025) | Viewed by 781

Special Issue Editor

Dr. Nobuhiro Kanaji

E-Mail Website
Guest Editor
Department of Internal Medicine, Division of Hematology, Rheumatology, and Respiratory Medicine, Faculty of Medicine, Kagawa University, Kagawa, Japan
Interests: lung cancer; interstitial lung disease

Special Issue Information

Dear Colleagues,

Over the past two decades, treatment for lung cancer has advanced dramatically. Two treatments that have made significant progress are molecular targeted therapy and immunotherapy. They have taken over the leading role from platinum drugs, leading to remarkable long-term survival.

In light of the dramatic advances in lung cancer treatment, we have planned this Special Issue to share the latest research findings on molecular targeted therapy and immunotherapy, discuss optimal treatment, recognize problems, and explore future directions.

We will accept a variety of manuscripts to address issues related to advances in lung cancer treatment, including original articles (clinical and basic studies) and reviews. For reviews, instead of immunotherapy as a whole, it is advisable to focus on more specific topics such as immunotherapy for the elderly, perioperative immunotherapy, ICI readministration, patients with autoimmune diseases, anti-PD-1 vs. anti-PD-L1, etc. As for molecular targeted therapy, not only EGFR and ALK but also low-frequency genetic abnormalities such as BRAF and MET can be categorized, and comparisons of multi-gene testing methods, TKI readministration, etc., are also acceptable. Topics such as image findings, artificial intelligence, or statistical analysis methods are also acceptable.

Dr. Nobuhiro Kanaji
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • lung cancer
  • molecular targeted therapy
  • immunotherapy
  • epidermal growth factor receptor
  • anaplastic lymphoma kinase
  • immune checkpoint inhibitor
  • driver gene
  • next-generation sequencing

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

16 pages, 6081 KiB  
Article
Immune Checkpoint Inhibitor-Induced Insidiously Progressive, Fatal Interstitial Lung Disease
by Nobuhiro Kanaji, Naoki Watanabe, Takuya Inoue, Hitoshi Mizoguchi, Yuta Komori, Yasuhiro Ohara and Norimitsu Kadowaki
J. Pers. Med. 2025, 15(3), 115; https://doi.org/10.3390/jpm15030115 - 15 Mar 2025
Viewed by 550
Abstract
Background/Objectives: Immune checkpoint inhibitors (ICIs) cause interstitial lung diseases (ILDs) as a type of immune-related adverse event (irAE). The characteristics of ICI-ILD are diverse. The objective of this study is to investigate the clinical features of ICI-ILD, with particular emphasis on insidiously progressive [...] Read more.
Background/Objectives: Immune checkpoint inhibitors (ICIs) cause interstitial lung diseases (ILDs) as a type of immune-related adverse event (irAE). The characteristics of ICI-ILD are diverse. The objective of this study is to investigate the clinical features of ICI-ILD, with particular emphasis on insidiously progressive ICI-ILD. Methods: We retrospectively analyzed 232 patients with advanced lung cancer who were treated with ICIs (including combination therapy with cytotoxic agents). Results: IrAEs were observed in 85 patients (36.6%). The most frequent irAE was ICI-ILD (41 patients, 17.7% of all patients). The occurrence of ICI-ILD was associated with a significantly better response compared to the non-irAE group (response rates: 88% vs. 33%), longer progression-free survival (PFS) (median: 17.5 vs. 3.0 months), and longer overall survival (median: 52.6 vs. 16.6 months), respectively. However, six patients died from ICI-ILD, which could be divided into two patterns: early-onset ICI-ILD in three patients (median PFS: 1.2 months), and insidiously progressive ICI-ILD in three patients. In the latter type, ICI-ILD developed unnoticed, progressed insidiously, and led to respiratory failure (median PFS: 7.2 months). The non-organizing pneumonia pattern and a weak response to corticosteroid therapy were also common findings. On average, six cycles of ICI treatment were administered between the time when ICI-ILD became retrospectively recognizable and the discontinuation of ICI treatment. During this period, C-reactive protein levels and the extent of ILD involvement gradually increased. Conclusions: Insidiously progressive ICI-ILD can lead to fatal outcomes. Early discontinuation of ICIs upon recognition of this type of ICI-ILD may improve patient outcomes. Full article
(This article belongs to the Special Issue New Insights into Targeted Therapy and Immunotherapy for Non-Small-Cell Lung Cancer)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop